PMID- 32070874
OWN - NLM
STAT- MEDLINE
DCOM- 20201210
LR  - 20201214
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 125
DP  - 2020 May
TI  - Preventive and curative effects of grape seed powder on stroke using in vitro and 
      in vivo models of cerebral ischemia/reperfusion.
PG  - 109990
LID - S0753-3322(20)30181-5 [pii]
LID - 10.1016/j.biopha.2020.109990 [doi]
AB  - Stroke is a worldwide concern. Many studies pointed out relevant preventive 
      effect of grape seed powder (GSP) against deleterious brain ischemia/reperfusion 
      (I/R) injury, but curative effect has been scarcely approached. The present work 
      aimed at studying the preventive and curative effect of GSP against stroke using 
      in-vitro and in-vivo models. Primary neuron-astrocyte cocultures were used to 
      evaluate in-vitro GSP protective and curative effect on 
      oxygen-glucose-deprivation (OGD). A murine I/R model, in which GSP was 
      administered as delayed post stroke drug, to evaluate its potential clinically 
      translatable therapy was used and behavioral tests were conducted after 15 days. 
      Ultra-structure of hippocampus dentate gyrus using Transmission Electron 
      Microscopy (TEM) was also undertaken. GSP prevented OGD-induced toxicity and cell 
      death in a dose dependent manner and was neuroprotective as assessed by sustained 
      cell viability (70 % +/-1 for OGD + GSP and 37 % +/-2 for OGD) and modulated 
      cytokines and brain derived neurotrophic factor (BDNF) expression. GSP also 
      promoted behavioral outcomes by increasing step-down inhibitory time from 17s+/-4 
      to 50s+/-11 and rat overall activities by improving scores in open field test to 
      near control level. Furthermore, GSP protected hippocampus dentate gyrus area 
      from I/R-induced drastic alterations as assessed by reduced autophagic vacuoles.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Kadri, Safwen
AU  - Kadri S
AD  - Bioactive Substances Laboratory, Biotechnology Centre, Technopolis Borj-Cedria, 
      BP-901, 2050, Hammam-Lif, Tunisia. Electronic address: kadri_safwen@live.fr.
FAU - El Ayed, Mohamed
AU  - El Ayed M
AD  - Bioactive Substances Laboratory, Biotechnology Centre, Technopolis Borj-Cedria, 
      BP-901, 2050, Hammam-Lif, Tunisia.
FAU - Limam, Ferid
AU  - Limam F
AD  - Bioactive Substances Laboratory, Biotechnology Centre, Technopolis Borj-Cedria, 
      BP-901, 2050, Hammam-Lif, Tunisia.
FAU - Aouani, Ezzedine
AU  - Aouani E
AD  - Bioactive Substances Laboratory, Biotechnology Centre, Technopolis Borj-Cedria, 
      BP-901, 2050, Hammam-Lif, Tunisia.
FAU - Mokni, Meherzia
AU  - Mokni M
AD  - Bioactive Substances Laboratory, Biotechnology Centre, Technopolis Borj-Cedria, 
      BP-901, 2050, Hammam-Lif, Tunisia.
LA  - eng
PT  - Journal Article
DEP - 20200225
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Antioxidants)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Polyphenols)
RN  - 0 (Powders)
RN  - IY9XDZ35W2 (Glucose)
RN  - S88TT14065 (Oxygen)
SB  - IM
MH  - Animals
MH  - Antioxidants/chemistry/pharmacology
MH  - Astrocytes/drug effects
MH  - Cell Survival/drug effects
MH  - Disease Models, Animal
MH  - Gas Chromatography-Mass Spectrometry
MH  - Glucose/chemistry
MH  - Hippocampus/metabolism/ultrastructure
MH  - Male
MH  - Mice
MH  - Neurons/drug effects
MH  - Neuroprotective Agents/*administration & dosage/chemistry
MH  - Oxygen/chemistry
MH  - Polyphenols/chemistry
MH  - Powders/*administration & dosage/chemistry
MH  - Rats
MH  - Reperfusion Injury/*drug therapy/etiology/pathology/*prevention & control
MH  - Seeds/*chemistry
MH  - Stroke/*drug therapy/etiology/pathology
MH  - Vitis/*chemistry
OTO - NOTNLM
OT  - Curative effect
OT  - GSP
OT  - I/R
OT  - OGD
OT  - Prevention
OT  - Stroke
COIS- Declaration of Competing Interest None.
EDAT- 2020/02/20 06:00
MHDA- 2020/12/15 06:00
CRDT- 2020/02/20 06:00
PHST- 2019/11/26 00:00 [received]
PHST- 2020/01/15 00:00 [revised]
PHST- 2020/01/31 00:00 [accepted]
PHST- 2020/02/20 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2020/02/20 06:00 [entrez]
AID - S0753-3322(20)30181-5 [pii]
AID - 10.1016/j.biopha.2020.109990 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2020 May;125:109990. doi: 10.1016/j.biopha.2020.109990. Epub 
      2020 Feb 25.